Monte Rosa Therapeutics (GLUE) Capital Expenditures Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.29 Bn | 1.61 Bn | - | 800.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 800.00% |
| Dec 31, 2025 | 92.28% |
| Sep 30, 2025 | -812.53% |
| Jun 30, 2025 | 22.91% |
| Mar 31, 2025 | -69.07% |
| Dec 31, 2024 | -121.13% |
| Sep 30, 2024 | 102.77% |
| Jun 30, 2024 | -62.79% |
| Mar 31, 2024 | -89.29% |
| Dec 31, 2023 | 117.76% |
| Sep 30, 2023 | -478.46% |
| Jun 30, 2023 | 4,391.03% |
| Mar 31, 2023 | 1,056.30% |
| Dec 31, 2022 | 751.32% |
| Sep 30, 2022 | 113.38% |
| Jun 30, 2022 | 113.90% |
| Mar 31, 2022 | -31.90% |
| Dec 31, 2021 | -6,165.00% |
| Sep 30, 2021 | 324.65% |